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1 Abstract 
2 Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large 
3 differences in BMD changes suggesting the mechanism of fracture risk reduction may 
4 differ among these agents.  Forty-eight intact (non-ovariectomized) skeletally mature 
5 female beagle dogs were treated orally for 12 months with clinically-relevant doses of 
6 risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 
7 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following 
8 measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) 
9 bone mineral densities, tissue mineralization by ash content, static and dynamic 
10 histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of 
11 biomechanical strength, stiffness and energy to fracture.  At these doses, RAL 
12 suppressed bone turnover (-20%) significantly less than the bisphosphonates (-66 and - 
13 71%), and did not produce significant differences in aBMD, vBMD, BV/TV or percent 
14 ash compared to VEH-treated animals. Microdamage accumulation in RAL-treated 
15 animals was not significantly different than VEH; both RIS and ALN had significantly 
16 higher crack surface density compared to VEH.  Stiffness was significantly higher than 
17 VEH in all treatment groups.  Ultimate load divided by aBMD, a measure of strength 
18 independent of BMD, was significantly higher only in RAL-treated animals compared to 
19 VEH (+16%, p = 0.015). Based on these data, we conclude that raloxifene produces 
20 improvements in bone mechanical properties in ways that do not involve increases in 
21 BMD. 22 
23 Key words: Bisphosphonates – SERMS – Osteoporosis – Microdamage – Biomechanics 
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1 Introduction 
2 Contributions to vertebral fracture risk reduction by factors other than bone mineral 
3 density (BMD) are suggested by data showing that anti-remodeling therapies reduce 
4 vertebral fracture risk by roughly the same degree (33-49% after the first 3 years of 
5 treatment) even though there is as much as a six-fold difference in the increase in spine 
6 BMD [1-7]. In addition, the risk of fracture to either the forearm [8] or the hip [9, 10] 
7 increases with age even at equivalent bone mineral density.  At the hip, for instance, the 
8 ten year probability of fracture for a woman with a T-score of -2 is about 4-fold greater at 
9 the age of 80 than at the age of 50 [9]. These findings, both from non-treated individuals 
10 and from those on therapy, demonstrate that bone strength and fracture risk are 
11 determined by more than areal bone mineral density (aBMD). 
12 Raloxifene, a selective estrogen receptor modulator (SERM), suppresses bone 
13 turnover and increases BMD by about half as much as the bisphosphonates (alendronate, 
14 risedronate, zoledronate) but reduces vertebral fracture risk by roughly the same degree. 
15 Three years of treatment with raloxifene (60 mg) reduces vertebral fractures in 
16 postmenopausal women by 30% [6] compared with 41-49% with risedronate [3, 4] or 44- 
17 47% with alendronate [1, 2]. The change in vertebral BMD with raloxifene treatment 
18 accounts for only 4% of the reduction in vertebral fracture risk [11], compared to 16-28% 
19 by bisphosphonates [12-14]. Together these data suggest some fundamental differences 
20 in the way these two classes of anti-remodeling agents reduce vertebral fracture risk. 
21 The goal of the current study was to determine if clinically-relevant doses of raloxifene 
22 alter properties of canine vertebral bone in ways that differ from the bisphosphonates. 23 
4  
1 Materials and Methods 
2 Animals 
3 Forty-eight skeletally mature female beagles (average age 1.3 ± 0.2 years) were 
4 purchased from Marshall Farms USA (North Rose, NY).  Upon arrival, lateral X-rays of 
5 all dogs were obtained to confirm skeletal maturity (closed proximal tibia and lumbar 
6 vertebra growth plates). Animals were housed two per cage in environmentally 
7 controlled rooms at Indiana University School of Medicine’s AALAC accredited facility 
8 and provided standard dog chow and water. All procedures were approved prior to the 
9 study by the Indiana University School of Medicine Animal Care and Use Committee. 10 
11 Experimental Design 
12 Following two weeks of acclimatization, animals were assigned to treatment groups 
13 (n=12/group) by matching body weights. All dogs were treated daily for 1-year with oral 
14 doses of vehicle (1 ml/kg/day saline), raloxifene (0.50 mg/kg/day, Lilly Research Labs, 
15 Indianapolis, IN), risedronate sodium (0.10 mg/kg/day, Procter and Gamble 
16 Pharmaceuticals, Inc, Cincinnati, OH) or alendronate sodium (0.20 mg/kg/day, Merck 
17 and Co., Inc., Rahway, NJ). The bisphosphonate doses were chosen to match those used 
18 for treatment of post-menopausal osteoporosis on an mg/kg basis while the raloxifene 
19 dose was chosen to produce serum levels equivalent to those documented in post- 
20 menopausal women.  Both risedronate and alendronate were dissolved in saline and 
21 administered to the dogs orally with a syringe. The raloxifene was diluted in 10% 
22 hydroxypropyl--cyclodextrin made with distilled water and administered orally with a 
5  
1 syringe. All drugs were administered in equivalent volumes (1 ml/kg/day) each morning 
2 after an overnight fast and at least 2 hours prior to feeding. 
3 Prior to necropsy, animals were injected with calcein (0.20 mL/kg, IV) using a 2-12- 
4 2-5 labeling schedule (9 animals per group) or a 2-5-2-5 (3 animals per group).  The 
5 shorter interlabel duration was due to a scheduling error. Animals were euthanized by 
6 intravenous administration of sodium pentobarbital (0.22mg/kg Beuthanasia-D Special). 
7 After death, thoracic and lumbar vertebrae were dissected and saved for analyses. The 
8 ninth thoracic and fourth lumbar vertebrae were separately wrapped in saline-soaked 
9 gauze and frozen (-20ºC).  Second and third lumbar vertebrae were fixed in 10% neutral 
10 buffered formalin. 
11 Densitometry 
12 Areal bone mineral density (aBMD, g/cm2) of the fourth lumbar vertebra (L4) was 
13 quantified using a PIXImus II densitometer (Lunar Corp.). Prior to scanning, the 
14 vertebrae were thawed to room temperature. The posterior elements and cranial/caudal 
15 endplates were removed using a low speed diamond saw (Labcut 1010, Extec) while 
16 under constant irrigation. Endplate removal was done such that surfaces were parallel for 
17 mechanical testing.  Scanning (0.18x 0.18 mm/pixel) was performed with the vertebral 
18 body laying on its medial surface. For each specimen, aBMD of the entire vertebral body 
19 was determined. 
20 Volumetric bone density and geometry of the L4 vertebra was quantified using a 
21 Norland Stratec XCT Research SA+ pQCT (Stratec Electronics). A scout view of each 
22 bone was obtained to determine slice locations. One slice (0.07 X 0.07 x 0.50 mm voxel 
23 size) was taken at three locations (25, 50 and 75% of total vertebra height).  Total and 
6  
1 trabecular volumetric bone mineral density (vBMD, mg/cm3) and cross-sectional area 
2 (CSA, mm2) were obtained for each slice using contour mode 1, peel mode 2, and a 
3 threshold of 710 mg/cm3.  Values from the three slices were averaged together to obtain a 
 
4 single representative value for each parameter for each specimen. 
 
5 Ash Weight 
 
6 Percent ash was quantified from the ninth thoracic vertebrae. Vertebrae were thawed to 
 
7 room temperature and a trabecular bone core (4 mm3) was cut from the mid-cranial 
 
8 metaphysis using a band saw (Marmed Inc.) while under constant irrigation. Trabecular 
 
9 bone specimens were dried using acetone/anhydrous ether and weighed daily until mass 
 
10 was stabilized for two consecutive days (dry weight). Bones were ashed at 800ºC for 12 
 
11 hours using a 1400 Thermolyne oven (Barnstead). Ashed specimens were allowed to 
 
12 cool and then weighed (ash weight). Percent ash was calculated as ash weight/dry weight 
 
13 * 100. 
 
14 Histology (Static, dynamic, and microdamage) 
 
15 Static and dynamic histomorphometric measures of trabecular bone were obtained on 
 
16 second lumbar vertebrae. After 3 days of fixation, bones were transferred to 70% ethanol 
 
17 until processing.  Using an automatic tissue processor (Shandon/Lipshaw), specimens 
 
18 were cycled through a graded series of ethanols, cleared using xylene, and infiltrated with 
 
19 methyl methacrylate (MMA; Aldrich).  Specimens were transferred to a solution of 
 
20 MMA + 3% dibutyl phthalate (DBP; Sigma-Aldrich) for 3-7 days under vacuum and then 
 
21 embedded using MMA + DBP + 0.25% catalyst (Perkadox 163; Akzo Nobel Chemicals). 
 
22 Mid-sagittal (4 µm) sections were cut using a Reichert-Jung 2050 microtome (Magee 
 
23 Scientific, Inc) and stained with McNeal’s tetrachrome for static histomorphometry. 
7  
1 Mid-sagittal (8 µm) sections were cut and left unstained for dynamic histomorphometry 
 
2 and wall thickness measures. 
 
3 Third lumbar vertebrae were processed for microdamage assessment by bulk staining 
 
4 in basic fuchsin [15]. Using 1% basic fuchsin dissolved in increasing concentrations of 
 
5 ethanol, specimens were stained according to the following schedule: 4 hours 80%, 4 
 
6 hours in new 80%, 4 hours in 95%, overnight in new 95%, 4 hours in 100%, 4 hours in 
 
7 new 100%. Bones were placed under vacuum (20 in Hg) for all stages during the day and 
 
8 left on the bench top overnight. Following staining, bones were washed 2x in 100% 
 
9 ethanol (five minutes each), placed in 100% MMA under vacuum for 4 hours, and then 
 
10 transferred to MMA + DBP for 3 days. Samples were embedded in MMA + DBP + 
 
11 0.25% catalyst. Mid-sagittal (80-100 µm) sections were cut using a diamond wire saw 
 
12 (Histosaw; Delaware Diamond Knives). 
 
13 Histological measurements were made using a semiautomatic analysis system 
 
14 (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope 
 
15 equipped with an ultraviolet light source (Nikon Optiphot 2 microscope, Nikon). 
 
16 Measurements were carried out on one stained (static), one unstained (dynamic), and two 
 
17 bulk stained (microdamage) sections per animal. Analysis of a single stained and 
 
18 unstained section has been previously shown to be sufficient to detect significant 
 
19 differences in this animal model [16] while two sections were measured for microdamage 
 
20 variables to reduce the probability of crackless specimens [17]. A 5 x 5 mm region of 
 
21 interest, located 1 mm below the cranial plateau, was used for sampling.  Static and 
 
22 dynamic variables were measured and calculated in accordance with ASBMR 
 
23 recommended standards [18]. Microdamage was assessed using UV fluorescence as 
8  
1 previously described [19]. Cracks were identified by their typical linear shape, relative 
 
2 size (greater than canaliculi, smaller than vascular channels), and positive fluorescence 
 
3 (due to diffusion of stain into the crack wall). Microcracks were identified at 10x 
 
4 magnification and their lengths measured at 20x magnification. Measurements included 
 
5 crack length (Cr.Le, µm) and crack number (Cr.N, #), with calculations of crack density 
 
6 (Cr.Dn, #/mm2; Cr.N / bone area) and crack surface density (Cr.S.Dn, µm/mm2; Cr.N * 
 
7 Cr.Le / bone area). 
 
8 Biomechanical Testing 
 
9 The biomechanical properties of fourth lumbar vertebrae were quantified using a 
 
10 servohydraulic testing system (MTS 810, MTS Corporation). Following densitometry, 
 
11 vertebral height was measured using digital calipers (Starrett #721; L.S. Starrett Co). 
 
12 Compression to failure was carried out on saline soaked specimens with displacement 
 
13 control mode (20 mm/min). Load versus displacement curves were recorded using a HP- 
 
14 7090 plotting system. Plots were analyzed for determination of ultimate force (maximum 
 
15 force obtained during test) and stiffness (slope of the linear portion of load/displacement 
 
16 curve). Work to ultimate force (area under the load/displacement curve before ultimate 
 
17 force) was measured by digitizing plots and analyzing the area using standard imaging 
 
18 software (Scion Image; Scion Corp.).  Ultimate stress (σult), elastic modulus (E), and 
 
19 toughness (U) were estimated using the following equations: 
 
20 σult = (ultimate force / CSA) / BV/TV 
 
21 E = (stiffness * (height / CSA)) / BV/TV 
 
22 U = (work to ultimate force / (height * CSA)) / BV/TV 
9  
1 where CSA is cross sectional area from pQCT measures of the same vertebrae (L4), 
 
2 height was that measured with digital calipers, and BV/TV was from histomorphometry 
 
3 of L2 histomorphometry. 
 
4 Statistics 
 
5 All statistical tests were performed using SAS software (SAS Institute, Inc.). 
 
6 Differences among treatment groups were evaluated using a one-way analysis of variance 
 
7 (ANOVA).  When a significant overall F value (p < 0.05) was present, differences 
 
8 between individual group means were tested using Fisher’s protected least-significant 
 
9 difference (PLSD) post-hoc test. For all tests, p < 0.05 was considered significant. All 
 
10 data are presented as mean ± standard error. 
 
11 Results 
 
12 At clinically relevant doses, raloxifene (RAL) had a smaller suppressive effect on bone 
 
13 remodeling in the lumbar vertebra than either of the bisphosphonates, risedronate (RIS) 
 
14 or alendronate (ALN). In this intact dog model, RAL suppressed activation frequency 
 
15 (Ac.f) by 20% compared to VEH-treated controls (p = 0.10), whereas RIS and ALN 
 
16 suppressed Ac.f by 66% and 71% respectively (p < 0.0001 versus both VEH and RAL) 
 
17 (Figure 1A). RIS and ALN each suppressed turnover by significantly reducing MS/BS (- 
 
18 50% versus VEH and RAL) and MAR (-25% versus VEH) (Table 1). Neither MS/BS 
 
19 nor MAR was significantly reduced with RAL-treatment compared to VEH. 
 
20 Only ALN-treated animals had significantly higher aBMD (p = 0.005) and total 
 
21 vBMD (p = 0.015) (Table 2) of the vertebra compared to VEH. Higher BMD in ALN, 
 
22 compared to VEH, occurred through a combination of higher percent ash (+ 3.6%, p = 
 
23 0.037) and trabecular bone volume (+ 20%, p = 0.015) (Tables 1 and 2). Compared to 
10  
1 VEH, neither percent ash nor bone volume were significantly different with RAL and in 
 
2 the RIS dogs only percent ash was significantly higher (Table 2). 
 
3 Even with a relatively low level of remodeling suppression, RAL-treated 
 
4 animals tended to have higher crack surface density (Cr.S.Dn) (2-fold higher vs VEH; p = 
 
5 0.14). Cr.S.Dn was significantly higher than VEH in both RIS (+2.9-fold) and ALN 
 
6 (+3.7-fold) groups; ALN-treated animals had significantly higher Cr.S.Dn compared to 
 
7 RAL (Figure 1B, Table 3). The non-significantly higher Cr.S.Dn with RAL was 
 
8 contrasted by a significantly higher mean crack length (p < 0.05 versus VEH; Figure 2, 
 
9 Table 3), whereas the significantly higher Cr.S.Dn in ALN and RIS groups was the result 
 
10 of a greater number of cracks (Figure 2, Table 3). 
 
11 Stiffness was significantly higher in all groups compared to VEH while there was 
 
12 no significant difference among groups for ultimate load or energy to ultimate load 
 
13 (Table 4). Normalization of ultimate load by aBMD, a measure of strength independent 
 
14 of bone density, revealed a significant increase in RAL-treated animals (+16%; p= 0.015) 
 
15 compared to VEH and ALN (Figure 1D). There was no significant difference in 
 
16 UL/aBMD for either ALN- or RIS-treated animals compared to VEH.  Vertebral 
 
17 toughness in ALN-treated dogs was significantly less than in RAL-treated dogs (-24%, p 
 
18 = 0.0007) and tended to be less than in VEH-treated dogs (-17%, p = 0.057) (Figure 1C). 
 
19 There was no significant difference among groups for other estimated material properties 
 
20 (ultimate stress or apparent modulus). 
 
21 Discussion 
 
22 Although routinely used as a surrogate of fracture risk, it is well accepted that bone 
 
23 density accounts for only a portion of bone strength [11-14]. In this study we attempted 
11  
1 to separate out the effects of these density-dependent parameters on vertebral bone 
 
2 strength. We found that raloxifene-treated animals had significantly higher vertebral 
 
3 strength (ultimate load) per unit aBMD compared to both vehicle- and alendronate- 
 
4 treated animals.  This is surprising in light of the fact that raloxifene treatment suppressed 
 
5 turnover and increased BMD less than the bisphosphonates. These observations are 
 
6 relevant as vertebral fracture risk reduction is often estimated based on changes in bone 
 
7 turnover rate or BMD following treatment, and suggests that raloxifene provides 
 
8 enhanced strength independent of bone volume or mineralization of the matrix. 
 
9 Bone strength is determined by multiple factors. At the material level, bone 
 
10 strength, stiffness, and energy absorption are influenced by mineral, collagen, and 
 
11 microdamage. Raloxifene-treated animals did not differ significantly from either 
 
12 bisphosphonate-treated group with respect to mineralization (percent ash). Microdamage 
 
13 accumulation (Cr.S.Dn) was significantly higher in raloxifene-treated animals compared 
 
14 to vehicle, and lower than alendronate-treated animals.  However, mean crack length was 
 
15 significantly higher with raloxifene treatment compared to all other groups. Despite 
 
16 these differences, select mechanical properties of raloxifene-treated animals were 
 
17 significantly higher compared to alendronate (both toughness and UL/aBMD) and vehicle 
 
18 (UL/aBMD). Given these differences, we suggest that bisphosphonates and raloxifene 
 
19 may differentially alter the collagen component of bone tissue. 
 
20 Estrogen and estrogen-like compounds are known to have an effect on collagen. 
 
21 Estrogens have been shown to inhibit the synthesis of advanced glycation end-products 
 
22 (AGEs) in epithelial tissue, the accumulation of which precipitates formation of non- 
 
23 enzymatic glycation crosslinks [20]. Tamoxifen inhibits ovariectomized-induced 
12  
1 increases in trabecular bone collagen glycation in rats [21]. Although hormone 
 
2 replacement therapy increase collagen cross-linking in post-menopausal women, studies 
 
3 have not measured non-enzymatic cross-links [22, 23]. We are not aware of any data 
 
4 regarding bisphosphonates and the formation of non-enzymatic crosslinks, although it is 
 
5 known from both in vitro [24-27] and in vivo [28-30] studies that increased pentosidine 
 
6 and vesperlysine, non-enzymatically-glycated cross-links, are associated with brittleness 
 
7 and reduced work to fracture of bone tissue. 
 
8 Raloxifene-induced changes in bone matrix properties without significantly 
 
9 changing BMD or BV/TV may help to explain its anti-fracture efficacy. In clinical trials, 
 
10 raloxifene induced a significant 2.6% increase in aBMD, but reduced vertebral fractures 
 
11 by 30% over three years [6]. These changes are contrasted by bisphosphoantes which 
 
12 increase spine BMD between 4.6 and 6.2% and reduce vertebral fracture risk by 41-49% 
 
13 [1-4]. The data presented in this paper suggest that raloxifene may alter properties of the 
 
14 bone matrix, and therefore help to prevent fractures by a mechanism that is relatively 
 
15 independent of BMD. This is contrasted by the bisphosphonates which derive a larger 
 
16 portion of their fracture risk reduction through increases in BMD. Indeed, the change in 
 
17 BMD with raloxifene has been shown to account for only 4% of the reduction in 
 
18 vertebral fracture risk [11], compared to 16-28% by bisphosphonates [12-14]. 
 
19 These results should be considered within the context of the various limitations of 
 
20 the current study. We used intact, non-ovariectomized beagle dogs and therefore it is 
 
21 unclear if similar changes with raloxifene-treatment would occur in the absence of 
 
22 estrogen. Additionally, for reasons unrelated to this study, serum analyses from three of 
 
23 the raloxifene-treated dogs were conducted after 7 months of treatment and revealed the 
13  
1 serum concentration of raloxifene was approximately ½ of what was predicted from the 
 
2 original dosing calculations.  However, these levels were still within the range of levels 
 
3 quantified in post-menopausal women receiving the 60 mg/day dose of raloxifene (Lilly 
 
4 data on file). Therefore we are confident that the changes with raloxifene compared to 
 
5 vehicle-treated animals represent changes that are clinically-relevant. As blood was not 
 
6 saved from bisphosphonate dogs we were not able to assess the serum concentration of 
 
7 these agents. So although the a priori dosing levels were all chosen to be equivalent to 
 
8 the clinical doses used for post-menopausal osteoporosis, we cannot exclude the 
 
9 possibility that differences between the bisphosphoantes and raloxifene treatments were 
 
10 due to these dosing discrepancies. 
 
11 In conclusion, we show raloxifene significantly improves vertebral bone strength 
 
12 independent of bone mineral density, and that this is a fundamentally different 
 
13 mechanism than occurs with either risedronate or alendronate. 14 
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1 Figure Legends 
 
2 Figure 1. Comparison of the effects of three anti-remodeling agents on (A) bone 
 
3 turnover measured by activation frequency, Ac,f; (B) crack surface density (Cr.S.Dn), a 
 
4 measure of microdamage accumulation; (C) toughness, the tissue-level energy absorption 
 
5 to ultimate stress; and (D) ultimate load normalized for areal bone mineral density, 
 
6 UL/aBMD. Data presented as mean ± SE. Numbers within bars represent % difference 
 
7 from VEH. P < 0.05 vs a VEH or b RAL. 8 
9 Figure 2. Frequency distribution showing that the higher amounts of damage 
 
10 accumulation in bisphosphonate treated animals was due to accumulation of many small 
 
11 cracks, whereas the smaller increase in damage accumulation in raloxifene-treated dogs 
 
12 was primarily the result of fewer but longer cracks. The distribution of crack lengths 
 
13 with raloxifene was similar to vehicle-treated control animals, but skewed to longer 
 
14 cracks than bisphosphonates. 
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